RNA sequencing reveals novel LncRNA/mRNAs co-expression network associated with puerarin-mediated inhibition of cardiac hypertrophy in mice

Shan Ye¹,², Weiyan Chen³, Caiwen Ou⁴ and Min-Sheng Chen¹

¹ Department of Cardiology, Laboratory of Heart Center, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Sino-Japanese Cooperation Platform for Translational Research in Heart Failure, Zhuhuiqiang Hospital, Southern Medical University, Guangzhou, PR China
² Department of Geriatrics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
³ Intensive Care Unit, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
⁴ Dongguan Hospital of Southern Medical University, Dongguan, Guangdong, China

ABSTRACT

Background: Evidence has demonstrated that puerarin is a potential medicine for the treatment of cardiac hypertrophy. However, the precise underlying molecular mechanisms of the protective effect of puerarin are still unclear. Here, we aimed to explore the regulatory mechanisms of LncRNAs/mRNAs co-expression network in a cardiac hypertrophy mouse model after puerarin treatment.

Methods: A mouse model of cardiac hypertrophy was established by transverse aortic constriction (TAC). The echocardiography, tissue staining and western blot were used to examine the protective effect of puerarin. Then RNA sequencing (RNA-seq) was carried out to analyze systematically mRNAs and LncRNAs expression. The target LncRNA were confirmed using qRT-PCR. Moreover, a coding/non-coding gene co-expression network were established to find the interaction of LncRNA and mRNAs. The biological process, cellular component, molecular function and pathways of different expression mRNAs targeted by LncRNA were explored using Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis.

Results: Puerarin exhibited an obvious inhibitory effect in cardiac hypertrophy in TAC model. RNA-seq analysis was performed to investigate the LncRNAs and mRNAs expression patterns of cardiomyocytes in sham and TAC groups treated with or without puerarin. RNA-seq identified that TAC downregulated four LncRNAs, which could be revised by puerarin treatment (|log2 Fold change| > 2 and FDR < 0.05). Among them, expression alterations of LncRNA Airn (antisense of Igf2r non-protein coding RNA) was confirmed by qRT-PCR. Pearson’s correlation coefficients of co-expression levels suggested that there was an interactive relationship between Airn and 2,387 mRNAs (r > 0.95 or r < −0.95). Those co-expressed mRNAs were enriched in some important biological processes such as translational initiation, cell proliferation, insulin-like growth factor binding and poly(A) RNA binding. KEGG analyses suggested that those Airn-interacted mRNAs...
were enriched in endocytosis, signaling pathways regulating pluripotency of stem cells and the Jak-STAT pathway.  
**Conclusion:** Puerarin may exert beneficial effects on cardiac hypertrophy through regulating the lncRNAs/mRNAs co-expression network.

**Subjects**  Biochemistry, Bioinformatics, Molecular Biology, Cardiology  
**Keywords** Long non-coding RNA, Message RNA, RNA sequencing, Cardiac hypertrophy, Puerarin

**INTRODUCTION**  
Left ventricular hypertrophy refers to the enlargement and thickening of the left ventricle walls. Developing left ventricular hypertrophy puts people at higher risk of myocardial infarction, heart failure and cardiac arrest (Mongiovi et al., 2010; Tang et al., 2020). It is demonstrated that cardiomyocyte hypertrophy is the main pathological change of left ventricular hypertrophy (Hutchings et al., 2018). However, there is no effective treatment for myocardial hypertrophy so far (Rodrigues, Leite-Moreira & Falcao-Pires, 2016). Therefore, it is urgent to find an effective treatment for cardiomyocyte hypertrophy.  
Puerarin (PUE) is an active component isolated from the Traditional Chinese Medicine Gegen (Zhang, 2019). Recently, it was found that puerarin could significantly inhibit cardiomyocyte hypertrophy. It was reported that puerarin prevented cardiac hypertrophy through regulating the AMPK, mTOR and Nrf2 pathway, suggesting that puerarin may be potential drug candidate for myocardial hypertrophy (Cai et al., 2018; Liu et al., 2015). However, the effect of puerarin on cardiomyocyte hypertrophy and its precise underlying molecular mechanisms need further study before its clinical usage for myocardial hypertrophy.  
Long non-coding RNA (lncRNA) is a kind of non-coding RNA with a length of more than 200 nucleotides (Statello et al., 2021b). Although lncRNAs do not code for proteins, they exert regulatory functions at various levels of gene expression, including chromatin modification, transcription, and post-transcription (Statello et al., 2021a, 2021b; Yang et al., 2020). Recently, the role of lncRNA in cardiovascular disease has attracted more and more attention. Many previous studies have found that lncRNA is abundant in the cardiovascular system, which is involved in the pathophysiological processes of heart development, myocardial remodeling, myocardial hypertrophy and cardiomyocyte apoptosis, etc. (Diao & Zhang, 2021; Gomes et al., 2020; Zhang, Yang & Qiu, 2021). Although current studies have demonstrated that lncRNAs play an important part in the pathophysiological process of cardiac disease, whether lncRNAs are associated with the protective role of puerarin in myocardial hypertrophy remains unknown. In the present study, RNA sequencing (RNA-seq) was performed to understand systematically the function of lncRNAs in the pharmacological action of puerarin in myocardial hypertrophy.
MATERIALS AND METHODS

Study design and transverse aortic constriction (TAC)-induced myocardial hypertrophy mouse model

Male C57BL/6 mice (aged 5 weeks old) used in this study were purchased from the Guangdong Medical Laboratory Animal Center (Guangzhou, China). The mice were fed a standard laboratory diet and housed under standard conditions. Two weeks later, a total of 15 mice were randomly assigned using computer-generated random number tables to sham group, TAC group and TAC+PUE group. The sham group mice received intraperitoneal (i.p.) injection of the saline and the surgical procedures without the constriction. TAC group mice received i.p. injection of the saline and the TAC procedures to induce cardiac hypertrophy. The TAC+PUE group mice received a daily i.p. injection of puerarin (Sigma Aldrich, St. Louis, MO, USA) 3 days before TAC and continued for 21 days after TAC. The doses administered for puerarin (100 mg/kg per day) were chosen based on previous studies (Chen et al., 2014).

TAC is widely used as a disease model of chronic ventricular hypertrophy (Bosch et al., 2020). Thereby, TAC was used to establish myocardial hypertrophy in mice as described in a previous study (Meng et al., 2018). Briefly, following anesthetization with isoflurane (Henry Schein, Melville, NY, USA), the aortic arch was exposed after a midline incision in the anterior neck. The transverse aortic arch between the left common carotid artery and the brachiocephalic artery was chosen as the site of constriction. The aortic arch was constricted by tying a 6.0 nylon suture ligature against a 26-gauge needle. After rapid removal of the needle, an incomplete constriction was formed. The successful constriction of TAC was verified using trans-thoracic echocardiography. All procedures were carried out according to the Guide for the Care and Use of Laboratory Animals (National Research Council (U.S.) et al., 2011). All animal experiments were approved by the Institutional Animal Care and Use Committee of the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (No. B2019-064).

Organ weight

Body weight (BW) and tibia length (TL) of each mouse were measured 21 days after the TAC procedure. The mice were sacrificed using cervical dislocation under anesthesia, and hearts were arrested in diastole with injection of potassium chloride. And then, the hearts were gained and heart weight (HW) were measured. Heart weight to body weight ratio (HW/BW) and heart weight to tibia length ratios (HW/TL) were counted.

Echocardiography

After anesthetization with isoflurane, successful ligation was confirmed by color Doppler and pulsed-wave Doppler scanning. Left ventricular posterior wall dimension (LVPWd) and interventricular end-diastolic septum thickness (IVSd) were measured by two-dimensional transthoracic echocardiography. The transthoracic echocardiography was performed by an experienced technician who was blinded to the study groups using an IE33 echocardiographic system (Philips Medical Systems, Leiden, the Netherlands).
Hematoxylin-eosin (HE) staining
After fixation with 10% formalin, the heart tissues were dehydrated through a serial alcohol gradient and embedded in paraffin wax blocks. And then, heart sections were stained with HE solution (Beyotime, China). The sections were examined under a light microscope (Nikon Technology Co., Ltd., Japan).

Western blot analysis
Western blot analysis was performed as described previously (Lin et al., 2018, 2021). Briefly, the whole protein of the heart was extracted using radio-immunoprecipitation assay (RIPA) lysis buffer (Kaiji Company, Shen Zhen, China) with protease and phosphatase inhibitors (Kaiji Company, Shen Zhen, China). Protein samples were separated by sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were then incubated at 4 °C overnight with the following primary antibodies: β-MHC (Bioworld Technology Inc., Louis Park, MN; USA; BS70815, 1:1,000) and GAPDH (Cell Signaling Technology Inc., Danvers, MA, USA; # 5174, 1:1,000). After being washed three times with PBST, the membranes were incubated with the secondary antibodies for 1 h at room temperature. Then, the signals were detected using the Imaging System (GE, Amersham Imager 600, GE, Piscataway, NJ, USA). The relative expression level of proteins was analyzed using Image-Pro Plus 6.0 (Media Cybernetics Inc., Bethesda, MD, USA).

RNA extraction
Three mice in each group were randomly selected to harvest the heart for the RNA sequence analysis. The mice were sacrificed at 21 days after TAC and hearts were harvested. Total RNA was isolated from heart tissues using Trizol reagent (TaKaRa, Tokyo, Japan). The concentration of the RNA samples was evaluated using a NanoDrop ND-1000 instrument (Thermo Fisher Scientific, Waltham, MA, USA). The integrity of the RNA was assessed by electrophoresis on an agarose gel.

RNA sequencing analysis
Library preparation and Illumina sequencing analysis were performed as previous study (Li et al., 2017). Briefly, the RNA of heart tissue was used for library construction by KAPA Stranded RNA-seq library Prep Kit (Illumina, NEB, San Diego, CA, USA). Then, the library was pair-end sequenced by Illumina NovaSeq 6000 Sequencing system (Illumina, NEB, San Diego, CA, USA) according to the manufacturer’s protocol. The whole-transcriptome sequencing experiment was completed by Kangcheng Biotechnology Co., Ltd. (Shanghai, China). The per base quality scores indicating the sequences data is of high quality. After trimming the adaptor sequences, clean sequences reads were obtained for subsequently analysis. Then the clean reads were mapped to a reference genome using Hisat2 software. The transcripts were assembled and quantitated by StringTie. The expression level of transcripts was measured by transcripts per kilobase million (TPM) values using the R package of Ballgown (Meng et al., 2021; Zhao et al., 2021b). The unknown transcripts were further screened with Coding Potential Assessing.
Tool (CPAT) to distinguish the protein-coding genes from the non-coding genes. The unknown non-coding transcripts were then used to screen for novel IncRNAs. The unknown non-coding transcripts with lengths more than 200 nt and more than two exons were selected as novel IncRNA candidates (Zhao et al., 2021a). Raw sequence files have been deposited at NCBI’s Gene Expression Omnibus (Accession code: GSE176244). Differentially expressed IncRNAs with statistical significance among the three groups were observed through volcano plot filtering. Hierarchical clustering was conducted to demonstrate the distinguishable IncRNAs expression pattern among the groups. The volcano plot filtering and hierarchical clustering analysis was conducted from the TPM values using the R package of ggrepthemes and pheatmap accordingly.

**Quantitative real-time polymerase chain reaction (qRT-PCR) analysis**
The IncRNA-seq results were further validated by qRT-PCR analysis as previous study (Lin et al., 2020). Briefly, total RNA isolated from heart tissues was reverse transcribed to synthesize cDNA using SuperScriptTM III Reverse Transcriptase kit (Invitrogen: 18080-044). Then, the qRT-PCR was performed by the QuantStudio5 Real-time PCR System (Applied Biosystems, Waltham, MA, USA) with the 2 × PCR Master Mix (Arraystar: AS-MR-006-5). Airn (antisense of Igf2r non-protein coding RNA) expression was determined using the 5′-CTAGCCACTGCGTGCCATA-3′ forward primer and 5′-TGGGTTACCCCTTGTCT-3′ reverse primer. Relative expression levels of Airn were normalized with GAPDH (Forward primer: 5′-CAGGAGCAGAGAGGCCCTCTAT-3′, Reverse primer: 5′-GCACCAGACTTTTTGATGTTAT-3′). The results were calculated using the $2^{-\Delta\Delta C_t}$ method. All groups had three independent samples and all of the samples were conducted in triplicate. Cq values obtained from the RT-qPCR testing were considered acceptable for technical triplicates if they fell within mean Cq ± 2 standard deviations (SD).

**Construction of the IncRNA-mRNA co-expression network**
The coding/non-coding gene co-expression (CNC) network profile was constructed according to validated altered IncRNA and its related mRNAs. The CNC was established through the weighted gene co-expression network analysis (WGCNA) using the R package WGCNA (v1.69) (Langfelder & Horvath, 2008). The co-expression network between mRNA and IncRNA was constructed utilizing Cytoscape version 2.8.1 software (The Cytoscape Consortium, San Diego, CA, USA) based on the Pearson correlation analysis of IncRNA and mRNA ($r > 0.95$ or $r < -0.95$).

**Gene function analysis**
To explore the function of the selected genes in the co-expression network, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for the targets genes were implemented using Database for Annotation, Visualization and Integrated Discovery (DAVID) (Lin et al., 2016).

**Statistical analysis**
All results were presented as the mean ± SD. Statistical analysis was performed using GraphPad Prism 7.0 software (San Diego, CA, USA). One-way ANOVA followed by
Tukey’s post hoc analysis was used to test the differences among groups. A $P$ value less than 0.05 was considered statistically significant.

**RESULTS**

**Puerarin inhibited TAC induced-cardiac hypertrophy in mice**

The ratio of heart weight to body weight or tibia length are useful indexes to quantify cardiac hypertrophy (Yin et al., 1982). As shown in Fig. 1A, the TAC group had significant high heart weight/body weight (HW/BW) ratio and heart weight/tibial length (HW/TL) ratio compared with sham group. Puerarin treatment resulted in a significant reduction of HW/BW and HW/TL ratio compared with TAC group. Echocardiography demonstrated that TAC resulted in the increase of LVPWd and IVSd, which were significantly reversed by puerarin (Fig. 1B). Besides, HE staining analysis of cardiac sections showed that the increased myocyte area in TAC mice was minimized by treatment with puerarin (Fig. 1C). Beta-myosin heavy chain ($\beta$-MHC) is a major component of cardiac myosin. The protein expression of $\beta$-MHC has historically been used as a marker...
of cardiac hypertrophy (Ding et al., 2019). Protein levels of β-MHC were detected by western blotting in this study. As expected, the protein expression of β-MHC increased dramatically in TAC mouse ventricular myocytes. Moreover, puerarin significantly reduced the β-MHC expression compared with TAC group (Fig. 1D).

IncRNA expression profiles and validation
RNA-seq was used to assess the expression levels of IncRNAs in heart samples of the sham, TAC and TAC+PUE groups. Overall, 32,105 IncRNAs were identified by RNA-seq among the groups. It was found that 23 IncRNAs were up-regulated and 716 were down-regulated in the TAC group compared with sham group (|log2 Fold change| > 2 and FDR < 0.05) through a volcano map (Fig. 2A). In addition, nine IncRNAs were up-regulated and one were down-regulated in TAC+PUE group compared with TAC group (|log2 Fold change| > 2 and FDR < 0.05) (Fig. 2B). Then, heat map showed that four IncRNAs downregulated in the TAC group were up-regulated by puerarin treatment (Fig. 3).

To validate the RNA-seq results, the IncRNA with most significant FDR value from the differentially expressed IncRNA profile was selected for the qRT-PCR analysis. The qRT-PCR results showed that there was significant difference among the groups in IncRNA Airn (P < 0.05) (Fig. 4).

IncRNA-mRNA network analysis
To investigate the underlying regulating mechanisms of Airn in cardiac hypertrophy and the therapeutic target of puerarin, we analyzed the co-expression of Airn and protein-coding genes by WGCNA. Pearson’s correlation coefficients of co-expression levels suggested that there was an interactive relationship between Airn and 2,387 mRNAs.
Those co-expressed genes including some important coding genes (Srf, Akt, Igf2, etc.) which have been reported to be involved in the pathogenesis of cardiac hypertrophy. We used Airn and the top 150 mRNAs co-expression with Airn to construct a lncRNA-mRNA visualization network using Cytoscape (Fig. 5).

Next, we carried out a functional enrichment analysis of the top 150 target genes using over-representation analysis. GO analysis found that these target mRNAs were enriched in some important biological processes and molecular function such as translational initiation, cell proliferation, insulin-like growth factor binding and poly(A) RNA binding (Figs. 6A–6C). KEGG analyses suggested that those Airn-interacted mRNAs were enriched in endocytosis, signaling pathways regulating pluripotency of stem cells and Jak-STAT pathway ($P < 0.05$) (Fig. 6D).
DISCUSSION

In the present study, we comprehensively investigated the role of lncRNAs in the cardioprotection of puerarin through RNA-seq. RNA-seq revealed that TAC downregulated four lncRNAs, which were reversed by puerarin treatment. Among them, Airn were verified by qRT-PCR. This data suggests that lncRNAs might be involved in the cardioprotection of puerarin. It was found that lncRNAs were significantly altered in the mouse model of cardiac hypertrophy, suggesting that lncRNAs might play an important role in the pathogenesis of cardiac hypertrophy (Wang et al., 2020). Previous studies demonstrated critical roles of particular lncRNAs such as Mhrt, Chaer and MEG3 in TAC mice. Those lncRNAs are proved to be candidates in the pathologic progression of hypertrophy cardiomyopathy (Liu, Zhang & Li, 2020; Xu et al., 2020). Our RNA-sequence results also found those dysregulated lncRNAs in cardiac tissue, and the change trend of those lncRNAs between the Sham and TAC groups was consistent with previous reports (Han et al., 2014;
However, those three dysregulated lncRNAs could not be reversed by puerarin according to our sequencing results. We found that lncRNA Airn, lncRNA Ttc4, lncRNA Ablim1 and lncRNA Nav3 were novel lncRNAs associated with cardiac hypertrophy. Moreover, we found that those dysregulated lncRNAs could be reversed by puerarin. Thus, those dysregulated lncRNAs might be promising therapeutic targets to suppress cardiac hypertrophy (Wang et al., 2020). Importantly, those four lncRNAs might be involved in puerarin-mediated inhibition of cardiac hypertrophy in mice.

Airn is a paternally expressed imprinted gene (Santoro et al., 2013). It located in antisense orientation to the maternally expressed Igf2r (insulin-like growth factor 2 receptor) gene (Latos et al., 2012). Although it is known that Airn and Igf2r are mutually
imprinted, up until now, the functions of Airn still need to be explored, especially in the cardiovascular system. A recent study reported that knockdown of Airn led to cardiomyocytes injury by reduced translation of Igf2bp2 (insulin-like growth factor 2 mRNA-binding protein 2) protein (Hosen et al., 2018). In this study, we found that the decreased expression of Airn is associated with cardiac hypertrophy in mice. In addition, we used the co-expression of Airn and protein-coding genes from the RNA-seq to investigate the underlying regulating mechanisms of Airn in cardiac hypertrophy and the therapeutic target of puerarin. Through WGCNA and Gene Ontology analysis, it was found that Airn was co-expressed with the insulin-like growth factor signalling pathway-related genes (Igf2, Igfbp4, Igfbp6, etc.). The result demonstrated that Airn might affect insulin-like growth factor signalling pathway-related genes and contribute to the cardiac hypertrophy in mice, which is consist with previous study (Diaz Del Moral et al., 2021; Hosen et al., 2018). The insulin-like growth factor pathway-related genes have been reported to play an important role in the occurrence and development of myocardial hypertrophy (Lu et al., 2021; Nomura et al., 2018; Zhang et al., 2021). The role of the Airn/insulin-like growth factor signalling pathway in cardiac hypertrophy, and whether this pathway is a drug target for puerarin in the treatment of cardiac hypertrophy needs to be further studied.

The limitation of this study is the lack of functional assessment of the identified lncRNA and mRNAs. Further mechanisms study will provide us a comprehensive understanding of puerarin pharmacological activities, which will be helpful for the development of clinical patient treatment and clinical practice guidelines.

In conclusion, our study used deep RNA-seq analysis to reveal that lncRNAs might be involved in the cardioprotection of puerarin. This study provides novel insights into our understanding of the pathogenesis of cardiac hypertrophy and proves the therapeutic role of puerarin in preventing or reversing cardiac hypertrophy.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**
This work was supported by the Medical Scientific Research Foundation of Guangdong Province, China (grant No. A2020106). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**
The following grant information was disclosed by the authors:
Medical Scientific Research Foundation of Guangdong Province: A2020106.

**Competing Interests**
The authors declare that they have no competing interests.
**Author Contributions**

- Shan Ye conceived and designed the experiments, performed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Weiyan Chen performed the experiments, prepared figures and/or tables, and approved the final draft.
- Caiwen Ou analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Min-Sheng Chen conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

**Animal Ethics**

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

All animal experiments were approved by the Institutional Animal Care and Use Committee of the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (No. B2019-064).

**Data Availability**

The following information was supplied regarding data availability:

The data is available at the NCBI Gene Expression Omnibus: GSE176244.

**Supplemental Information**

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.13144#supplemental-information.

**REFERENCES**

Bosch L, de Haan JJ, Bastemeijer M, van der Burg J, van der Worp E, Wesseling M, Viola M, Odille C, El Azzouzi H, Pasterkamp G, Sluijter JPG, Wever KE, de Jager SCA. 2020. The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis. *Heart Failure Reviews* 26(6):1515–1524 DOI 10.1007/s10741-020-09960-w.

Cai SA, Hou N, Zhao GJ, Liu XW, He YY, Liu HL, Hua YQ, Li LR, Huang Y, Ou CW, Luo CF, Chen MS. 2018. Nrf2 is a key regulator on puerarin preventing cardiac fibrosis and upregulating metabolic enzymes UGT1A1 in rats. *Frontiers in Pharmacology* 9:540 DOI 10.3389/fphar.2018.00540.

Chen G, Pan SQ, Shen C, Pan SF, Zhang XM, He QY. 2014. Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-kappaB pathways. *Acta Pharmacologica Sinica* 35(4):463–475 DOI 10.1038/aps.2013.185.

Diao L, Zhang Q. 2021. Transfer of lncRNA UCA1 by hUCMSCs-derived exosomes protects against hypoxia/reoxygenation injury through impairing miR-143-targeted degradation of Bcl-2. *Aging* 13(4):5967–5985 DOI 10.18632/aging.202520.

Diaz Del Moral S, Benaouicha M, Munoz-Chapuli R, Carmona R. 2021. The insulin-like growth factor signalling pathway in cardiac development and regeneration. *International Journal of Molecular Sciences* 23(1):234 DOI 10.3390/ijms23010234.
Ding J, Tang Q, Luo B, Zhang L, Lin L, Han L, Hao M, Li M, Yu L, Li M. 2019. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-beta1 signaling pathway. *European Journal of Pharmacology* 859(5):172549 DOI 10.1016/j.ejphar.2019.172549.

Gomes CPda C, Schroen B, Kuster GM, Robinson EL, Ford K, Squire IB, Heymans S, Martelli F, Emanueli C, Devaux Y, On behalf of the EU-CardioRNA COST Action (CA17129). 2020. Regulatory RNAs in heart failure. *Circulation* 141(4):313–328 DOI 10.1161/CIRCULATIONAHA.119.042474.

Han P, Li W, Lin CH, Yang J, Shang C, Nuernberg ST, Jin KK, Xu W, Lin CY, Lin CJ, Xiong Y, Chien H, Zhou B, Ashley E, Bernstein D, Chen PS, Chen HV, Quertermous T, Chang CP. 2014. A long noncoding RNA protects the heart from pathological hypertrophy. *Nature* 514:102–106 DOI 10.1038/nature13596.

He Z, Zeng X, Zhou D, Liu P, Han D, Xu L, Bu T, Wang J, Ke M, Pan X, Du Y, Xue H, Lu D, Luo B. 2021. LncRNA Chaer prevents cardiomyocyte apoptosis from acute myocardial infarction through AMPK activation. *Frontiers in Pharmacology* 12:649398 DOI 10.3389/fphar.2021.649398.

Hosen MR, Militello G, Weirick T, Ponomareva Y, Dassanayaka S, Moore JB, Doring C, Wysoczynski M, Jones SP, Dimmeler S, Uchida S. 2018. Airn regulates Igf2bp2 translation in cardiomyocytes. *Circulation Research* 122(10):1347–1353 DOI 10.1161/CIRCRESAHA.117.312215.

Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. 2018. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? *Heart* 104(15):1244–1250 DOI 10.1136/heartjnl-2017-312865.

Langfelder P, Horvath S. 2008. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* 9(1):559 DOI 10.1186/1471-2105-9-559.

Latos PA, Pauler FM, Koerner MV, Senergin HB, Hudson QJ, Stocsits RR, Allhoff W, Stricker SH, Klement RM, Warczok KE, Aumayr K, Pasierbek P, Barlow DP. 2012. Airn transcriptional overlap, but not its lncRNA products, induces imprinted Igf2r silencing. *Science* 338:1469–1472 DOI 10.1126/science.1228110.

Li H, Wei X, Yang J, Dong D, Huang Y, Lan X, Plath M, Lei C, Qi X, Bai Y, Chen H. 2017. Developmental transcriptome profiling of bovine muscle tissue reveals an abundant GosB that regulates myoblast proliferation and apoptosis. *Oncotarget* 8(19):32083–32100 DOI 10.18632/oncotarget.16644.

Lin SP, Hu J, Wei JX, Ye S, Bu J, Xu W, Chen S, Wu Y, Wu G, Zhu L, Lin PY, Chen XH. 2020. Silencing of circFoxO3 protects HT22 cells from glutamate-induced oxidative injury via regulating the mitochondrial apoptosis pathway. *Cellular and Molecular Neurobiology* 40(7):1231–1242 DOI 10.1007/s10571-020-00817-2.

Lin SP, Li W, Winters A, Liu R, Yang SH. 2018. Artemisinin prevents glutamate-induced neuronal cell death via akt pathway activation. *Frontiers in Cellular Neuroscience* 12:108 DOI 10.3389/fncel.2018.00108.

Lin SP, Wei JX, Hu JS, Bu JY, Zhu LD, Li Q, Liao HJ, Lin PY, Ye S, Chen SQ, Chen XH. 2021. Artemisinin improves neurocognitive deficits associated with sepsis by activating the AMPK axis in microglia. *Acta Pharmacologica Sinica* 42(7):1069–1079 DOI 10.1038/s41401-021-00634-3.

Lin SP, Ye S, Long Y, Fan Y, Mao HF, Chen MT, Ma QJ. 2016. Circular RNA expression alterations are involved in OGD/R-induced neuron injury. *Biochemical and Biophysical Research Communications* 471(1):52–56 DOI 10.1016/j.bbrc.2016.01.183.
Liu B, Wu Z, Li Y, Ou C, Huang Z, Zhang J, Liu P, Luo C, Chen M. 2015. Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. Biochemical and Biophysical Research Communications 464(3):908–915 DOI 10.1016/j.bbrc.2015.07.065.

Liu L, Zhang D, Li Y. 2020. LncRNAs in cardiac hypertrophy: from basic science to clinical application. Journal of Cellular and Molecular Medicine 24(20):11638–11645 DOI 10.1111/jcmm.15819.

Lu J, Ma X, Gao WC, Zhang X, Fu Y, Liu Q, Tian XD, Yang W, Zheng HY, Zheng CB. 2021. Gastrodin exerts cardioprotective action via inhibition of insulin-like growth factor Type 2/insulin-like growth factor type 2 receptor expression in cardiac hypertrophy. ACS Omega 6(26):16763–16774 DOI 10.1021/acsomega.1c00797.

Meng F, Du N, Xu D, Kuai L, Liu L, Xiu M. 2021. Bioinformatics analysis of the molecular mechanism and potential treatment target of ankylosing spondylitis. Computational and Mathematical Methods in Medicine 2021:7471291 DOI 10.1155/2021/7471291.

Meng G, Liu J, Liu S, Song Q, Liu L, Xie L, Han Y, Ji Y. 2018. Hydrogen sulfide pretreatment improves mitochondrial function in myocardial hypertrophy via a SIRT3-dependent manner. British Journal of Pharmacology 175(8):1126–1145 DOI 10.1111/bph.13861.

Mongiovi M, Fesslova V, Fazio G, Barbaro G, Pipitone S. 2010. Diagnosis and prognosis of fetal cardiomyopathies: a review. Current Pharmaceutical Design 16(26):2929–2934 DOI 10.2174/138161210793176428.

National Research Council (U.S.), Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.). 2011. Guide for the care and use of laboratory animals. 8th Edition. Washington, D.C.: National Academies Press. xxv, 220.

Nomura S, Satoh M, Fujita T, Higo T, Sumida T, Ko T, Yamaguchi T, Tobita T, Naito AT, Ito M, Fujita K, Harada M, Toko H, Kobayashi Y, Ito K, Takimoto E, Akazawa H, Morita H, Aburatani H, Komuro I. 2018. Cardiomyocyte gene programs encoding morphological and functional signatures in cardiac hypertrophy and failure. Nature Communications 9(1):4435 DOI 10.1038/s41467-018-06639-7.

Piccoli MT, Gupta SK, Viereck J, Foinquinos A, Samolovac S, Kramer FL, Garg A, Remke J, Zimmer K, Batkai S, Thum T. 2017. Inhibition of the cardiac fibroblast-enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction. Circulation Research 121(5):575–583 DOI 10.1161/CIRCRESAHA.117.310624.

Rodrigues PG, Leite-Moreira AF, Falcao-Pires I. 2016. Myocardial reverse remodeling: how far can we rewind? American Journal of Physiology-Heart and Circulatory Physiology 310(11):H1402–H1422 DOI 10.1152/ajpheart.00696.2015.

Santoro F, Mayer D, Klement RM, Warczok KE, Stukalov A, Barlow DP, Pauler FM. 2013. Imprinted Igf2r silencing depends on continuous Airn lncRNA expression and is not restricted to a developmental window. Development 140(6):1184–1195 DOI 10.1242/dev.088849.

Statello L, Ali MM, Reischl S, Mahale S, Kosalai ST, Huarte M, Kanduri C. 2021a. The DNA damage inducible lncRNA SCAT7 regulates genomic integrity and topoisomerase 1 turnover in lung adenocarcinoma. NAR Cancer 3(1):zcab002 DOI 10.1093/narcancer/zcab002.

Statello L, Guo CJ, Chen LL, Huarte M. 2021b. Gene regulation by long non-coding RNAs and its biological functions. Nature Reviews Molecular Cell Biology 22(2):96–118 DOI 10.1038/s41580-020-00315-9.

Tang L, Yu X, Zheng Y, Zhou N. 2020. Inhibiting SLC26A4 reverses cardiac hypertrophy in H9C2 cells and in rats. PeerJ 8(5):e8253 DOI 10.7717/peerj.8253.
Wang L, Wang J, Li G, Xiao J. 2020. Non-coding RNAs in physiological cardiac hypertrophy. *Yeast Membrane Transport* 1229:149–161 DOI 10.1007/978-981-15-1671-9.

Xu Y, Luo Y, Liang C, Zhang T. 2020. LncRNA-Mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p/KLF4/myocardin axis. *Journal of Molecular and Cellular Cardiology* 139:47–61 DOI 10.1016/j.yjmcc.2019.12.013.

Yang Q, Han Y, Liu P, Huang Y, Li X, Jia L, Zheng Y, Li W. 2020. Long noncoding RNA GAS5 promotes osteogenic differentiation of human periodontal ligament stem cells by regulating GDF5 and p38/JNK signaling pathway. *Frontiers in Pharmacology* 11:701 DOI 10.3389/fphar.2020.00701.

Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML, Lakatta EG. 1982. Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. *American Journal of Physiology* 243(6):H941–H947 DOI 10.1152/ajpheart.1982.243.6.H941.

Zhang L. 2019. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. *Drug Delivery* 26(1):860–869 DOI 10.1080/10717544.2019.1660732.

Zhang Y, Da Q, Cao S, Yan K, Shi Z, Miao Q, Li C, Hu L, Sun S, Wu W, Wu L, Chen F, Wang L, Gao Y, Huang Z, Shao Y, Chen H, Wei Y, Chen F, Han Y, Xie L, Ji Y. 2021. HINT1 (Histidine Triad Nucleotide-Binding Protein 1) attenuates cardiac hypertrophy via suppressing HOXA5 (Homeobox A5) expression. *Circulation* 144(8):638–654 DOI 10.1161/CIRCULATIONAHA.120.051094.

Zhang L, Yang C, Qiu B. 2021. LncRNA RP11-400K9.4 aggravates cardiomyocytes apoptosis after hypoxia/reperfusion injury by targeting miR-423. *International Heart Journal* 62(5):1124–1134 DOI 10.1536/ihj.20-828.

Zhao S, Chen T, Luo X, Chen S, Wang J, Lai S, Jia X. 2021a. Identification of novel lncRNA and differentially expressed genes (DEGs) of testicular tissues among cattle, yak, and cattle-yak associated with male infertility. *Animals* 11(8):2420 DOI 10.3390/ani11082420.

Zhao Y, Li MC, Konate MM, Chen L, Das B, Karlovich C, Williams PM, Evrard YA, Doroshow JH, McShane LM. 2021b. TPM, FPKM, or normalized counts? A comparative study of quantification measures for the analysis of RNA-seq data from the NCI patient-derived models repository. *Journal of Translational Medicine* 19(1):269 DOI 10.1186/s12967-021-02936-w.